CESCA THERAPEUTICS INC. | Business Contracts

Amendment No. 3 to First Amended and Restated Revolving Credit Agreement, dated March 6, 2023, between ThermoGenesis Holdings, Inc. and Boyalife Group Inc (Filed With SEC on March 10, 2023)

Amended 2016 Equity Incentive Plan (Filed With SEC on December 20, 2022)

Amendment to the Amended and Restated Certificate of Incorporation of ThermoGenesis Holdings, Inc (Filed With SEC on December 20, 2022)

Lease Agreement, dated March 24, 20222, between ThermoGenesis Holdings, Inc. and Z3 Investment LLC (Filed With SEC on March 28, 2022)

License and Technology Access Agreement, dated March 24, 2022, between ThermoGenesis Holdings, Inc. and Boyaife Genomics Tianjin Ltd (Filed With SEC on March 28, 2022)

Supply Agreement between BioHit Healthcare (Hefei) Co., Ltd. and ThermoGenesis Holdings, Inc. dated August 11, 2020 (Filed With SEC on August 14, 2020)

Joint Venture Agreement, dated as of October 21, 2019, between Cesca Therapeutics Inc. and Healthbanks Biotech (USA) Inc (Filed With SEC on October 22, 2019)

Amendment No. 2 to Second Amended and Restated Convertible Promissory Note, dated March 6, 2023, between ThermoGenesis Holdings, Inc. and Boyalife Group Inc (Filed With SEC on March 10, 2023)

Amendment No. 3 to Convertible Promissory Note, dated January 31, 2023, between ThermoGenesis Holdings, Inc. and Orbrex (USA) Co. Limited (Filed With SEC on February 6, 2023)

Form of Common Warrant (Filed With SEC on October 17, 2022)

Form of Securities Purchase Agreement (Filed With SEC on October 17, 2022)

Engagement Letter Amendment, dated October 14, 2022, between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 17, 2022)

Amendment No. 2 to Convertible Promissory Note, dated July 25, 2022, between ThermoGenesis Holdings, Inc. and Orbrex (USA) Co. Limited (Filed With SEC on July 28, 2022)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on May 27, 2022)

Form of Securities Purchase Agreement (Filed With SEC on April 29, 2022)

Engagement Letter, dated as of March 8, 2022, between ThermoGenesis Holding, Inc. and H.C. Wainright & Co., LLC (Filed With SEC on April 29, 2022)

Form of Pre-Funded Warrant (Filed With SEC on April 29, 2022)

Form of Common Warrant (Filed With SEC on April 29, 2022)

Amendment No. 2 to First Amended and Restated Revolving Credit Agreement, dated March 4, 2022, between ThermoGenesis Holdings, Inc. and Boyalife Asset Holding II, Inc (Filed With SEC on March 8, 2022)

Amendment No. 1 to Second Amended and Restated Convertible Promissory Note, dated March 4, 2022, between ThermoGenesis Holdings, Inc. and Boyalife Asset Holding II, Inc (Filed With SEC on March 8, 2022)

Amendment No. 2 to At the Market Offering Agreement, dated February 3, 2022, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on February 3, 2022)

Amended 2016 Equity Incentive Plan (Filed With SEC on January 14, 2022)

Fourth Amendment to the Companys Amended. 2016 Equity Incentive Plan, effective June 4, 2020 (Filed With SEC on January 14, 2022)

Payment Protection Program Loan (PPP Loan) between ThermoGenesis Holdings, Inc. and Comerica Bank dated April 21, 2020 (Filed With SEC on August 14, 2020)

Manufacturing and Supply Amending Agreement #2, effective as of July 13, 2020, between ThermoGenesis Holdings, Inc. and CBR Systems, Inc (Filed With SEC on July 17, 2020)

Fourth Amendment to the ThermoGenesis Holdings, Inc. 2016 Equity Incentive Plan, effective June 4, 2020 (Filed With SEC on June 9, 2020)

Form of Stock Option Agreement (Filed With SEC on June 9, 2020)

Amendment No. 1 to At The Market Offering Agreement, dated May 19, 2020, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 20, 2020)

Supply Agreement, effective as of April 22, 2020, between ThermoGenesis Corp. and ImmuneCyte Life Sciences Inc (Filed With SEC on April 28, 2020)

Engagement Agreement, dated as of March 24, 2020, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on March 27, 2020)

Form of Securities Purchase Agreement, dated as of March 25, 2020, between ThermoGenesis Holdings, Inc. and the Purchasers identified on the signature pages thereto (Filed With SEC on March 27, 2020)

Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 24, 2020)

Manufacturing and Supply Amending Agreement #1, effective as of March 16, 2020, between ThermoGenesis Corp. and CBR Systems, Inc (Filed With SEC on March 20, 2020)

Form of Stock Option Award Agreement (Filed With SEC on January 3, 2020)

Stockholders Agreement, dated November 22, 2019, among ThermoGenesis Holdings, Inc., Healthbanks Biotech (USA) Inc. and ImmuneCyte Life Sciences Inc (Filed With SEC on November 27, 2019)

Contribution Agreement, dated November 22, 2019, between ThermoGenesis Holdings, Inc. and ImmuneCyte Life Sciences Inc (Filed With SEC on November 27, 2019)

Supply Agreement, dated November 22, 2019, between ThermoGenesis Holdings, Inc. and ImmuneCyte Life Sciences Inc (Filed With SEC on November 27, 2019)

Amendment No. 1, dated July 23, 2019, to the Convertible Promissory Note, dated January 29, 2019 between Cesca therapeutics Inc. and Orbrex USA Co (Filed With SEC on November 19, 2019)

Supply Agreement, dated as of August 30, 2019, between Corning Incorporated and Cesca Therapeutics Inc (Filed With SEC on September 6, 2019)

Cesca Therapeutics Inc. Amended 2016 Equity Incentive Plan (Filed With SEC on August 13, 2019)

Amendment No. 1 to the Convertible Promissory Note, Dated July 23, 2019 between Cesca therapeutics Inc. and Orbrex USA Co (Filed With SEC on August 13, 2019)

Amendment No. 1 to the Convertible Note Agreement dated as of July 23, 2019, between Cesca Therapeutics Inc. and Orbrex USA Co (Filed With SEC on July 29, 2019)

Securities Purchase Agreement, dated as of July 23, 2019, between Cesca Therapeutics Inc. and the Purchaser identified on the signature pages thereto (Filed With SEC on July 29, 2019)

Form of Note (Filed With SEC on July 29, 2019)

Third Amendment to Cesca Therapeutics Inc. Amended 2016 Equity Incentive Plan, dated December 14, 2018 (Filed With SEC on June 4, 2019)

Securities Purchase Agreement, dated as of April 18, 2019, between Cesca Therapeutics Inc. and the Purchaser identified on the signature pages thereto (Filed With SEC on April 25, 2019)

Form of Pre-Funded Warrant (Filed With SEC on April 25, 2019)

Voting Agreement between CARTXpress Bio, Inc. and Bay City Capital Fund V, L.P. and Bay City Capital Management V LLC (Filed With SEC on March 26, 2019)

Securities Purchase Agreement, dated as of January 29, 2019, between Cesca Therapeutics Inc. and the Purchasers identified on the signature pages thereto (Filed With SEC on January 31, 2019)

Form of Note (Filed With SEC on January 31, 2019)

Reorganization and Share Exchange Agreement, dated January 1, 2019, among ThermoGenesis Corp., Cesca Therapeutics Inc., CARTXpress Bio, Inc., Bay City Capital Fund V. L.P. and Bay... (Filed With SEC on January 4, 2019)

Amended and Restated Certificate of Incorporation of CARTXpress Bio, Inc (Filed With SEC on January 4, 2019)

Right of First Refusal and Co-Sale Agreement, dated January 1, 2019, among CARTXpress Bio, Inc., ThermoGenesis Corp., Bay City Capital Fund V, L.P., and Bay City Capital Fund V... (Filed With SEC on January 4, 2019)

Investors Rights Agreement, dated January 1, 2019, among CARTXpress Bio, Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P (Filed With SEC on January 4, 2019)

Voting Agreement, dated January 1, 2019, among CARTXpress Bio, Inc., ThermoGenesis Corp., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P (Filed With SEC on January 4, 2019)

CESCA THERAPEUTICS INC. (55)